Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Sosei Group Corporation

Company price
9.75 USD -0.75 ( 7.14%)
Last update at 2026-11-20T14:30:00Z
VOLUME
1150
Market Cap
805.25M

Momentum Score

…

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
9.75
Low
9.75
High
52 Week Price Range
8.93
Low
22.78
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
10.50
Dividend Yield
-
Revenue TTM
12402.00M
Revenue Per Share
151.10
Gross Profit TTM
14643.00M
Debt / Equity
0.51
ROE
-5.94%
Net Debt
-36823.00M
ROCE
3.85%
Diluted EPS TTM
-0.29

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 1078.00M 433.00M 1622.00M 534.00M -9046.00M
Minority interest - 0.00M 0.00M 3.00M 3.00M
Net income 382.00M 1017.00M 1479.00M 1432.00M -6918.00M
Selling general administrative 4377.00M 3940.00M 3435.00M 3614.00M 2387.00M
Gross profit 14643.00M 16779.00M 8081.00M 8875.00M 3215.00M
Reconciled depreciation 1345.00M 1278.00M 1350.00M 1489.00M -
Ebit 3670.00M 4024.00M 2200.00M 1027.00M -7911.00M
Ebitda 5015.00M 5302.00M 3550.00M 2516.00M -
Depreciation and amortization 1345.00M 1278.00M 1350.00M 1489.00M -
Operating income 3436.00M 3775.00M 928.00M 384.00M -7911.00M
Other operating expenses 12133.00M 13937.00M 7914.00M 9342.00M 290.00M
Interest expense 756.00M 3797.00M 578.00M 493.00M 0.00M
Tax provision 696.00M -584.00M 143.00M -898.00M -
Interest income 663.00M 199.00M 1628.00M 824.00M -
Net interest income -93.00M -3598.00M 1050.00M 331.00M -
Extraordinary items - - - - 0.00M
Non recurring - - - - 0.00M
Other items - - - - 0.00M
Income tax expense 696.00M -584.00M 143.00M -898.00M -2127.00M
Total revenue 15569.00M 17712.00M 8842.00M 9726.00M 3550.00M
Total operating expenses 11207.00M 13004.00M 7153.00M 8491.00M 11461.00M
Cost of revenue 926.00M 933.00M 761.00M 851.00M 335.00M
Total other income expense net -2358.00M -3342.00M 694.00M 150.00M -1135.00M
Discontinued operations - - - - 0.00M
Net income from continuing ops 382.00M 1017.00M 1479.00M 1432.00M -6919.00M
Net income applicable to common shares 382.00M 1017.00M 1479.00M 1432.00M -6918.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 99417.00M 96985.00M 76465.00M 56680.00M 58987.00M
Intangible assets 8577.00M 9120.00M 11802.00M 12999.00M 14367.00M
Other current assets 865.00M 427.00M 651.00M 499.00M 480.00M
Total liab 41481.00M 39517.00M 24084.00M 11602.00M 17407.00M
Total stockholder equity 57936.00M 57468.00M 52381.00M 45075.00M 41577.00M
Deferred long term liab - - - - 0.00M
Other current liab 2288.00M 5822.00M 1307.00M 917.00M 375.00M
Common stock 41335.00M 41036.00M 40220.00M 37479.00M 36854.00M
Capital stock 41335.00M 41036.00M 40220.00M 37479.00M -
Retained earnings -8911.00M -9768.00M -10785.00M -12264.00M -13696.00M
Other liab 7831.00M 3248.00M 4646.00M 7595.00M 7988.00M
Good will 15306.00M 15095.00M 14134.00M 14365.00M 14177.00M
Other assets - 102.00M 7.00M - 0.00M
Cash 66557.00M 60087.00M 40008.00M 15375.00M 18760.00M
Total current liabilities 4092.00M 7191.00M 2985.00M 2303.00M 5449.00M
Current deferred revenue 296.00M 279.00M 29.00M 162.00M -
Net debt -36823.00M -30816.00M -23385.00M -13496.00M -
Short term debt 176.00M 193.00M 170.00M 175.00M 2987.00M
Short long term debt - - - 175.00M 2987.00M
Short long term debt total 29734.00M 29271.00M 16623.00M 1879.00M -
Other stockholder equity 25512.00M 26200.00M 22946.00M 19860.00M -7623.00M
Property plant equipment 3791.00M 3817.00M 3824.00M 4120.00M 2715.00M
Total current assets 69942.00M 62808.00M 42018.00M 19563.00M 22284.00M
Long term investments - - - 5633.00M 5444.00M
Net tangible assets 34053.00M 33253.00M 26445.00M 17711.00M 13033.00M
Short term investments - 86.00M - - 0.00M
Net receivables 2462.00M 2241.00M 1671.00M 3689.00M 3044.00M
Long term debt 27981.00M 27440.00M 14789.00M 1704.00M 3940.00M
Inventory - - - - 0.00M
Accounts payable 1628.00M 1176.00M 1508.00M 1211.00M 2080.00M
Total permanent equity - - - - 0.00M
Noncontrolling interest in consolidated entity - - - - 0.00M
Temporary equity redeemable noncontrolling interests - - - - 0.00M
Accumulated other comprehensive income - - - - 0.00M
Additional paid in capital - - - - 0.00M
Common stock total equity - - - - 0.00M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - 0.00M
Treasury stock - - - - 0.00M
Non currrent assets other 1801.00M 188.00M 4687.00M 5633.00M -
Non current assets total 29475.00M 34177.00M 34447.00M 37117.00M -
Capital lease obligations 1753.00M 1831.00M 1834.00M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1043.00M 206.00M 238.00M -250.00M -650.00M
Change to liabilities 315.00M -984.00M 61.00M -258.00M 185.00M
Total cashflows from investing activities 1043.00M 278.00M -150.00M -246.00M -3252.00M
Net borrowings - 29855.00M 15902.00M -7061.00M -3005.00M
Total cash from financing activities -4887.00M 11123.00M 20278.00M -6964.00M -3274.00M
Change to operating activities 4780.00M 3001.00M -683.00M 848.00M 1208.00M
Net income 1078.00M 433.00M 1622.00M 534.00M -6918.00M
Change in cash 6470.00M 20079.00M 24633.00M -3385.00M -13377.00M
Begin period cash flow 60087.00M 40008.00M 15375.00M 18760.00M 28281.00M
End period cash flow 66557.00M 60087.00M 40008.00M 15375.00M 18760.00M
Total cash from operating activities 9952.00M 7095.00M 4672.00M 3441.00M -6047.00M
Issuance of capital stock 0.00M 600.00M 5145.00M 747.00M -
Depreciation 1345.00M 1278.00M 1350.00M 1489.00M 1153.00M
Other cashflows from investing activities 137.00M 273.00M 294.00M 284.00M -2.00M
Dividends paid - - - - 0.00M
Change to inventory - - - - 0.00M
Change to account receivables -210.00M -799.00M 752.00M -923.00M 10.00M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities -4887.00M 29481.00M 15133.00M -650.00M -213.00M
Change to netincome 2644.00M 3366.00M 1570.00M 1751.00M 443.00M
Capital expenditures 303.00M 201.00M 105.00M 280.00M 2231.00M
Change in working capital 5258.00M -1783.00M 1364.00M 258.00M -
Stock based compensation 700.00M 713.00M 626.00M 384.00M -
Other non cash items 1571.00M 6454.00M -290.00M 776.00M -
Free cash flow 9649.00M 6894.00M 4567.00M 3161.00M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SOLTF
Sosei Group Corporation
-0.75
7.14%
9.75 - - 0.07 1.99 0.08 -1.38
NVO
Novo Nordisk A/S
-1.06
2.73%
37.81 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-5.64
1.08%
515.02 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
-
-%
920.69 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Sosei Group Corporation

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

PMO Hanzomon, Tokyo, Japan, 102-0083

81 3 5210 3290

348

Name Title Year Born
Mr. Shinichi Tamura Founder & Chairman 1949
Mr. Chris Cargill Representative Exec. Officer, Pres, CEO & Director 1984
Mr. Hironoshin Nomura Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO NA
Mr. Kieran Johnson F.C.A. Exec. Officer, VP & Chief Accounting Officer NA
Dr. Miles Congreve Chief Scientific Officer NA
Mr. Kazuhiko Yoshizumi Exec. Officer, VP & Chief Compliance Officer 1954
Candelle Chong VP of Corp. Strategy & Communications NA
Shinichiro Nishishita VP of Investor Relations & Head of Regulatory Disclosures NA
Dr. Barry Kenny Ph.D. Chief Bus. Officer of Bus. Devel. NA
Stacey Southall Associate Director & Head of Biophysics NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…